

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

CREON® (pancrelipase)

PANCREAZE® (pancrelipase)

PERTZYE® (pancrelipase)

VIOKACE® (pancrelipase)

ZENPEP® (pancrelipase)

Generic Equivalent (if available)

This Pharmacy Coverage Guideline (PCG):

- Provides information about the reasons, basis, and information sources we use for coverage decisions
- Is not an opinion that a drug (collectively “Service”) is clinically appropriate or inappropriate for a patient
- Is not a substitute for a provider’s judgment (Provider and patient are responsible for all decisions about appropriateness of care)
- Is subject to all provisions e.g. (benefit coverage, limits, and exclusions) in the member’s benefit plan; and
- Is subject to change as new information becomes available.

Scope

- This PCG applies to Commercial and/or Marketplace plans
- This PCG does not apply to the Federal Employee Program, Medicare Advantage, Medicaid or members of out-of-state Blue Cross and/or Blue Shield Plans

Instructions & Guidance

- To determine whether a member is eligible for the Service, read the entire PCG.
- This PCG is used for FDA approved indications including, but not limited to, a diagnosis and/or treatment with dosing, frequency, and duration.
- Use of a drug outside the FDA approved guidelines, refer to the appropriate Off-Label Use policy.
- The “Criteria” section outlines the factors and information we use to decide if the Service is medically necessary as defined in the Member’s benefit plan.
- The “Description” section describes the Service.
- The “Definition” section defines certain words, terms or items within the policy and may include tables and charts.
- The “Resources” section lists the information and materials we considered in developing this PCG
- **We do not accept patient use of samples as evidence of an initial course of treatment, justification for continuation of therapy, or evidence of adequate trial and failure.**
- Information about medications that require prior authorization is available at www.azblue.com/pharmacy. You must fully complete the [request form](#) and provide chart notes, lab workup and any other supporting documentation. The prescribing provider must sign the form. Fax the form to BCBSAZ Pharmacy Management at (602) 864-3126 or email it to Pharmacyprecert@azblue.com.

Medical Necessity Requirements for **CREON** (pancrelipase), **PANCREAZE** (pancrelipase), **PERTZYE** (pancrelipase), and **ZENPEP** (pancrelipase)

Criteria for Initial Therapy:

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

Prescriber Qualifications

- Prescribed by a physician specializing in the diagnosis or is in consultation with a Gastroenterologist or Pulmonologist

Indication

- Exocrine Pancreatic Insufficiency confirmed by **ONE** of the following:
 - Cystic fibrosis with suspected or known exocrine pancreatic insufficiency
 - Chronic pancreatitis, pancreatectomy, or other known condition associated with exocrine pancreatic insufficiency with at least **FOUR** of the following:
 1. Post meal abdominal pain or cramping
 2. Bloating
 3. Excessive gas
 4. Greasy stools or steatorrhea
 5. Frequent loose stools
 6. Unexplained weight loss
 7. Deficiency in fat soluble vitamins (A, D, E, and K)
 - No established condition associated with exocrine pancreatic insufficiency with **BOTH** of the following:
 1. Pancreatic function test consistent with exocrine pancreatic insufficiency (e.g., fecal elastase 1, fecal chymotrypsin, serum trypsinogen, secretin stimulation test)
 2. At least **FOUR** of the signs and symptoms listed above

Age Requirement

- Age is consistent with FDA approved product labeling

Alternative Therapies

- **For Pancreaze and Pertzye:** Failure, contraindication, intolerance, or is not a candidate for **BOTH** of the following:
 - Creon
 - Zenpep

Brand Specific Criteria

- Have failure, contraindication or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- Other causes of chronic diarrhea, bloating, excessive gas, and steatorrhea ruled out (e.g., small intestinal bacterial overgrowth, celiac disease, giardiasis)
- No concomitant use of other pancreatic enzyme replacement therapy (e.g., Creon, Pancreaze, Pertzye, Viokace, Zenpep)

Documentation Requirements

- A completed request form must be submitted including:
 - Chart notes
 - Lab results (pancreatic function tests)
 - Supporting clinical documentation

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

Initial Therapy Criteria Approval Duration

- 6 months OR end of plan year
-

Criteria for Continuation of Therapy (renewal therapy):

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.

Prescriber Qualification

- Continues to be seen by a physician specializing in or is in consultation with a Gastroenterologist or Pulmonologist

Clinical Response

- **TWO** of the following:
 - Decrease in abdominal pain or cramping
 - Decrease in diarrhea (improved stool consistency)
 - Resolution of fatty stools or steatorrhea
 - Weight gain
 - Improvement in fat soluble vitamin deficiencies

Adherence

- Adherence to the prescribed therapy regimen has been documented

Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No significant adverse drug effects such as fibrosing colonopathy
- No concomitant use of other pancreatic enzyme replacement therapy

Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values confirming safe use

Continuation Therapy Criteria Approval Duration

- 12 months OR end of plan year
-

Medical Necessity Requirements for **VIOKACE** (pancrelipase)

Criteria for Initial Therapy:

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

Prescriber Qualifications

- Prescribed by a physician specializing in the diagnosis or is in consultation with a Gastroenterologist

Age Requirement

- 18 years or older

Indication

- Exocrine Pancreatic Insufficiency with chronic pancreatitis or pancreatectomy with **FOUR** of the following:
 - Post meal abdominal pain or cramping
 - Bloating
 - Excessive gas
 - Greasy stools or steatorrhea
 - Frequent loose stools
 - Unexplained weight loss
 - Deficiency in fat soluble vitamins (A, D, E, and K)

Alternative Therapies

- Documented failure, contraindication, intolerance, or not a candidate for **BOTH** of the following:
 - Creon
 - Zenpep

Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- To be used in combination with a proton pump inhibitor (e.g., omeprazole, pantoprazole, lansoprazole, esomeprazole)
- Other causes of chronic diarrhea, bloating, excessive gas, and steatorrhea ruled out
- No concomitant use of other pancreatic enzyme replacement therapy (e.g., Creon, Pancreaze, Pertzye, Zenpep)

Documentation Requirements

- A completed request form must be submitted including:
 - Chart notes
 - Lab results
 - Supporting clinical documentation

Initial Therapy Criteria Approval Duration

- 6 months OR end of plan year

Criteria for Continuation of Therapy (renewal therapy):

Note: Manufacturer assistance (e.g., coupons, samples, etc.) are not considered for continuation of therapy.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

Prescriber Qualification

- Continues to be seen by a physician specializing in or is in consultation with a Gastroenterologist

Clinical Response

- **TWO** of the following:
 - Decrease in abdominal pain or cramping
 - Decrease in diarrhea (improved stool consistency)
 - Resolution of fatty stools or steatorrhea
 - Weight gain
 - Improvement in fat soluble vitamin deficiencies

Adherence

- Adherence to the prescribed therapy regimen has been documented

Brand Specific Criteria

- Have failure, contraindication, or intolerance with **THREE** generic equivalents (if available) for at least three months each. **Note:** Any failure, contraindication, or intolerance to the generic drugs should be reported to the FDA (see Definitions section)

Safety

- No significant adverse drug effects such as fibrosing colonopathy
- To be used in combination with a proton pump inhibitor
- No concomitant use of other pancreatic enzyme replacement therapy

Documentation Requirements

- Chart notes
- Supporting clinical documentation with evidence of improvement in given indication
- Lab values confirming safe use

Continuation Therapy Criteria Approval Duration

- 12 months OR end of plan year
-

Criteria for Off-Label Use Requests:

Criteria for a request for non-FDA use or indication, treatment with dosing, frequency, or duration outside the FDA-approved dosing, frequency, and duration, refer to one of the following Pharmacy Coverage Guideline:

1. Off-Label Use of Non-Cancer Medications
 2. Off-Label Use of Cancer Medications
-

Description:

Exocrine pancreatic insufficiency (EPI) is defined as inadequate activity or deficiency of the pancreatic enzymes within the intestinal lumen, resulting in maldigestion and malabsorption. EPI is the consequence of several

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

different diseases which result in inadequate enzyme digestion. Mechanisms of EPI include inadequate synthesis and secretion of pancreatic enzymes, decreased stimulation, pancreatic ductal obstruction and decreased pancreatic enzyme activity in the small bowel. The most common causes of EPI are cystic fibrosis, chronic pancreatitis, and pancreatectomy, but other pancreatic conditions may lead to EPI as well.

Mild EPI may be asymptomatic or cause mild abdominal pain and bloating. Bowel movements are usually normal appearing. Moderate to severe EPI causes bloating, cramping, flatulence, and steatorrhea. Overt steatorrhea occurs when approximately 90 percent of the glandular function of the pancreas is lost. Symptoms of steatorrhea include loose greasy, foul-smelling stools that are difficult to flush. This results in maldigestion of fat and protein and weight loss.

In individuals with well-established chronic pancreatitis, cystic fibrosis, pancreatectomy, or another underlying pancreatic disease such as pancreatic adenocarcinoma, a clinical diagnosis of EPI can be made based on symptoms. If the diagnosis is unclear or the individual does not have an established underlying disease, pancreatic function tests are used to confirm the diagnosis. Once EPI is confirmed, the individual should still be evaluated for the cause of pancreatic dysfunction. Pancreatic enzymes should not be used as a test or trial to determine if someone has pancreatic insufficiency.

The mainstay of treatment for EPI is pancreatic enzyme replacement therapy (PERT). PERT serve as exogenous versions of hormones and enzymes required for normal digestion. The FDA approved PERTs have been given the generic name pancrelipase. They are porcine enzymes and contain mixtures of pancreatic lipase, amylase, and protease. Lipase is a digestive enzyme involved in the hydrolysis and degradation of fats. Impairments in lipase metabolism leads to the malabsorption of fats. Amylase is a digestive enzyme involved in the hydrolysis and digestion of starches. Impairments in amylase metabolism leads to complex carbohydrates malabsorption. Proteases are enzymes involved in the breakdown of proteins and amino acids. Imbalances or insufficiency of proteases can lead to poor absorption of amino acids and breakdown of essential proteins.

Pancreatic enzyme products have been available in the United States since before the 1938 passage of the Food, Drug and Cosmetic Act. In 2004, the Food and Drug Administration (FDA), declared that pancreatic enzyme products require new FDA approval by 2010, or they would be removed from the market. This and helping standardize the manufacturing process and require the labeling of the amount of lipase in each capsule.

Definitions:

U.S. Food and Drug Administration (FDA) MedWatch Forms for FDA Safety Reporting
[MedWatch Forms for FDA Safety Reporting | FDA](#)

Underlying causes of pancreatic exocrine insufficiency:

- Chronic pancreatitis
- Cystic fibrosis
- Main pancreatic duct obstruction (adenocarcinoma, intraductal papillary mucinous neoplasm, pancreas divisum, etc.).
- Pancreatectomy
- Gastric resection
- Short bowel syndrome
- Hereditary hemochromatosis
- Alpha 1 antitrypsin deficiency

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

- Shwachman-Diamond-Oski syndrome

Delayed-release capsule containing enteric-coated microtablets, porcine origin.

Pancreatic Enzyme Products:

Pancrelipase preparations	Description	Lipase (USP units)	Amylase (USP units)	Protease (USP units)
Pancreaze 2600	Delayed-release capsule containing enteric-coated microtablets, porcine origin.	2600	15,200	8800
Pancreaze 4200		4200	24,600	14,200
Pancreaze 10,500		10,500	61,500	35,500
Pancreaze 16,800		16,800	98,400	56,800
Pancreaze 21,000		21,000	83,900	54,700
Pancreaze 37,000		37,000	149,000	97,300
Creon 3	Delayed-release capsule containing enteric-coated minimicrospheres, porcine origin	3000	15,000	9500
Creon 6		6000	30,000	19,000
Creon 12		12,000	60,000	38,000
Creon 24		24,000	120,000	76,000
Creon 36		36,000	180,000	114,000
Zenpep 3	Delayed-release capsule containing enteric-coated beads, porcine origin.	3000	14,000	10,000
Zenpep 5		5000	24,000	17,000
Zenpep 10		10,000	42,000	32,000
Zenpep 15		15,000	63,000	47,000
Zenpep 20		20,000	84,000	63,000
Zenpep 25		25,000	105,000	79,000
Zenpep 40		40,000	168,000	126,000
Viokace 10,440	Regular-release (non-enteric-coated) tablet, porcine origin.	10,440	39,150	39,150
Viokace 20,880		20,880	78,300	78,300
Pertzye 4	Delayed-release capsule containing bicarbonate-buffered, enteric-coated microspheres, porcine origin.	4000	15,125	14,375
Pertzye 8		8000	30,250	28,750
Pertzye 16		16,000	60,500	57,500
Pertzye 24		24,000	90,750	86,250

Resources:

Creon (pancrelipase) delayed-release cap product information, revised by manufacturer AbbVie Inc. 02-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed November 03, 2025.

Pancreaze (pancrelipase) delayed-release cap product information, revised by manufacturer Vivus LLC. 05-2025. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed November 03, 2025.

Pertzye (pancrelipase) delayed-release cap product information, revised by manufacturer Digestive Care, Inc. 02-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed November 03, 2025.

Viokace (pancrelipase) tab product information, revised by manufacturer Aimmune Therapeutics, Inc. 07-2025. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed November 03, 2025.

Zenpep (pancrelipase) delayed-release cap product information, revised by manufacturer Aimmune Therapeutics, Inc. 10-2024. Available at DailyMed <http://dailymed.nlm.nih.gov>. Accessed November 03, 2025.

Gardner TB, Adler DG, Forsmark CE, et al. ACG Clinical Guideline: Chronic Pancreatitis. Am J Gastroenterol 2020; 115:322-339. Re-evaluated February 01, 2026.

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.



An Independent Licensee of the Blue Cross Blue Shield Association

PHARMACY COVERAGE GUIDELINE

PANCREATIC ENZYME REPLACEMENT THERAPIES:

Arvanitakis M, Ockenga J, Bezmarevic M, et al. ESPEN guideline on clinical nutrition in acute and chronic pancreatitis. *Clinical Nutrition*. 2020; 39:612-631. Re-evaluated February 01, 2026.

Freedman SD, Forsmark CE. Chronic pancreatitis: Management. In: UpToDate, Adler DG, Meyer C (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated March 04, 2024. Accessed February 01, 2026.

Stevens T, Conwell DL. Exocrine pancreatic insufficiency. In: UpToDate, Adler DG, Meyer C (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated November 06, 2025. Accessed February 01, 2026.

Sabharwal S, Schwarzenberg SJ. Cystic fibrosis: Overview of gastrointestinal disease. In: UpToDate, Chmiel JF, Heyman MB, Hoppin AG. (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated May 13, 2025. Accessed February 01, 2026.

Schwarzenberg SJ, Baker SS. Cystic fibrosis: Assessment and management of pancreatic insufficiency. In: UpToDate, Chmiel, JF, Heyman MB, Hoppin AG. (Eds), UpToDate, Waltham MA.: UpToDate Inc. Available at <http://uptodate.com>. Literature current through December 2025. Topic last updated June 03, 2025. Accessed February 01, 2026.

ORIGINAL EFFECTIVE DATE: 02/15/2024 | ARCHIVE DATE: | LAST REVIEW DATE: 02/19/2026 | LAST CRITERIA REVISION DATE:

BLUE CROSS®, BLUE SHIELD® and the Cross and Shield Symbols are registered service marks of the Blue Cross and Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. All other trademarks and service marks contained in this guideline are the property of their respective owners, which are not affiliated with BCBSAZ.